RNai, siRNA and miRNA

Venue: Crowne Plaza Hotel

Location: London, United Kingdom

Event Date/Time: Jun 28, 2010 End Date/Time: Jun 29, 2010
Early Registration Date: Mar 31, 2010
Report as Spam


SMi 5th conference on RNAi, siRNA and miRNA will build on the success of the past four years, bringing together the leading experts in industry and academia to explore the cutting edge of new therapeutics being researched and brought to the marketplace. It will combine a study of the latest successes in the research and development phase with presentations covering the key themes of delivery, target identification and IP issues.

Key themes at this year’s conference will be:


• Delivery
• Gene silencing
• Preclinical studies
• Target identification


• Delivery, technology and applications
• Immunology
• New approaches for nucleic acid based therapeutics


• Regulation of gene expression
• Immune system regulation
• Therapeutic strategies

Here Keynote address from:

• Michael Keller, Senior Fellow, siRNA Project Leader, Technical Research and Development (TRD), Novartis
• Ken Clark, Director, Respiratory siRNA DPU, GlaxoSmithKline
• Herbert Muller-Hartmann, Director, R&D, Lonza
• Peter Jackson, Chief Operating Officer, Medesis Pharma
• Jörg Vollmer, Managing Director, Pfizer Oligonucleotide Therapeutics Unit (Dusseldorf)
• Chris Kitson, Investigator, GlaxoSmithKline

Our expert speaker line-up also includes:

• Aimee Jackson, Director of Drug Discovery, Regulus Therapeutics
• Dmitry Samarsky, VP, Technology Development, RXi Pharmaceuticals
• Claude Paul Malvy, Director, IFSBM, Universite Paris-Sud
• Jesper Wengel, Professor, Nucleic Acid Centre, University of Southern Denmark
• Suzy Lena Wengel, CEO, RiboTask
• Victoria Gonzalez, Preclinical Manager, Sylentis (Zeltia Group)
• Georg Sczakiel, Professor, Institute for Molecular Medicine, Lubeck University
• Roberto GuercioliniDicerna Pharmaceuticals
• Lorna Brazell, Partner, Bird & Bird
• Elena Bichenkova, Senior Lecturer in Medicinal Chemistry, University of Manchester
• Karl-Hermann Schlingensiepen, CEO, Antisense Pharma
• Dimitris Lagos, Cancer Research UK Viral Oncology Group
• Elena Vigorito, Group Leader, Lymphocyte Signalling & Development, Babraham Institute
• Marie-Andree Yessine, Scientist, OctoPlus Development